UNSPSC 51182068: Testosterone cyclopentanepropionate

This classification denotes an androgen with the molecular formula C27H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M0XW1UBI14, chemically known as androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17.beta.)-, but more generally known as testosterone cyclopentanepropionate, which bears US NIH Compound Identifier 6012. European Medicines Agency schedules testosterone cyclopentanepropionate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG.

Most nations, for tariff purposes, schedule testosterone cyclopentanepropionate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=CC(=O)CC[C@]35C.

UNSPSC 51182068 Testosterone cyclopentanepropionate is a Commodity code representing a specific pharmaceutical active ingredient that state and local procurement bodies source as part of broader generic multi-source pharmaceutical supply agreements. Based on recent solicitation activity, state and local governments acquire this and similar generic pharmaceutical products through cooperative purchasing vehicles that consolidate demand across multiple participating jurisdictions and authorize distribution through contracted wholesalers. The work involves manufacturers submitting detailed product specifications (National Drug Codes, SKUs, UPCs, strength, dosage form, packaging configurations) and agreeing to pricing structures—flat price, net price formats, or WAC-minus—while maintaining compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Issuing bodies under this code include multistate cooperative purchasing alliances and the state agencies that administer them; the Minnesota Department of Administration's Office of State Procurement, which manages the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), represents a significant buyer consolidating demand across multiple states including Oregon and participating local government facilities.

The Minnesota Multistate Cooperative Purchasing Alliance issued a Request for Proposal on January 20, 2026 (S1070000015802) for Generic Multi Source Pharmaceuticals and OTC Products with a March 26, 2026 response deadline, establishing multiple contracts effective July 1, 2026 with a two-year term and optional extensions. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), carry comprehensive insurance including $5 million commercial general liability and $2 million network security and privacy liability, and accept a 3 percent administrative fee with performance penalties of $200 to $1,500 per violation. The solicitation weights price competitiveness most heavily at 75 percent of evaluation, with smaller components for fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and fee agreement (5 percent). No specific award value or set-aside designations are disclosed; opportunities in this code appear concentrated in multistate cooperative purchasing activity centered in the Upper Midwest and Pacific Northwest.